Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.
Yes, Bill’s commitment remains aligned with our priority areas. Each year, the foundation allocates around $8.4 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback